long half-life and large variability [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2020-08-12 15:53 (49 d 19:03 ago) – Posting: # 21865
Views: 487

Hi Achievwin,

» Welcome to the home of funky and funny pharmacokinetics where "Garbage in Gospel out" is day of life.

:-D

» 1. allowing long washout periods have seen studies with 4 -5 months washout.

Seen a couple as well.

» 2. other choice we can imagine is Two stage adaptive study design and including ANCOA in place of ANOVA...

Slippery grounds – nothing published. You are on your own to demonstrate that the Type I Error is controlled. For the FDA and Health Canada likely simulations are sufficient. For the EMA no way.
I’m a fan of TSDs but if you proceed to the second stage it more than doubles the time of study compared to a fixed sample design. With fast to moderate half lives not an issue. But here?

Furthermore, reference-scaling for HVD(P)s in a TSD is not possible. Some tried, all studies were rejected due to potential inflation of the TIE.

Dif-tor heh smusma 🖖
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

Activity
 Admin contact
21,091 posts in 4,398 threads, 1,469 registered users;
online 17 (0 registered, 17 guests [including 5 identified bots]).
Forum time: Thursday 10:56 CEST (Europe/Vienna)

In these days, a man who says a thing cannot be done
is quite apt to be interrupted by some idiot doing it.    Elbert Green Hubbard

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5